You can now read 10 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe


Ariad leukemia drug put on FDA fast track

Decision due in March on leukemia treatment; Cambridge company doubles workforce

Federal regulators have granted priority review to a closely watched leukemia drug candidate developed by Ariad Pharmaceuticals Inc., promising to decide by March 27 whether the Cambridge company can start selling the treatment.

Priority review is typically extended to medicines that may work better than existing treatments, or are effective in patients who haven’t responded to drugs already on the market.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week